Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Combined treatment of allograft recipients with anti-CD40 ligand and CTLA-4Ig (costimulation blockade) is a powerful promising albeit not consistently tolerizing therapy. It would be desirable to use an effective conventional immunosuppressive regimen in low doses or for a short course as an adjunct; however, cyclosporine treatment drastically blunts the ability of costimulation blockade to produce long-term engraftment. METHODS: Short courses of cyclosporine or rapamycin were compared as adjuncts to costimulation blockade in the murine BALB/c to C3H/He heterotopic cardiac allograft model. RESULTS: Although cyclosporine therapy blocked the capacity of costimulation blockade to produce permanent engraftment, combined rapamycin and costimulation blockade treatment produced permanent engraftment. CONCLUSION: A theoretical basis for the differing effects of cyclosporine and rapamycin upon the outcome of costimulation blockade is forwarded. Combined use of costimulation blockade and rapamycin may provide a means to bring costimulation blockade into the clinic.

publication date

  • November 27, 1998

Research

keywords

  • Antigens, Differentiation
  • Graft Rejection
  • Immunoconjugates
  • Immunosuppressive Agents
  • Sirolimus

Identity

Scopus Document Identifier

  • 0345164351

Digital Object Identifier (DOI)

  • 10.1097/00007890-199811270-00021

PubMed ID

  • 9846527

Additional Document Info

volume

  • 66

issue

  • 10